Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
NCT ID: NCT03628131
Last Updated: 2018-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
46 participants
INTERVENTIONAL
2018-10-31
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
NCT02638428
Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours
NCT02303028
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
NCT01956669
Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents
NCT01535183
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
NCT03709680
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pazopanib + conventional chemotherapy
Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
Pazopanib
Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
Ifosfamide
Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
Carboplatin
Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
Etoposide
Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pazopanib
Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
Ifosfamide
Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
Carboplatin
Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
Etoposide
Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients previously enrolled to "Genomic diagnosis of pediatric tumors by NGS (IRB No. SMC 2015-11-053)"
Exclusion Criteria
* Patients with organ dysfunction as follows (creatinine elevation ≥ 1.5 x upper limit of normal (ULN), ejection fraction \<40%, significant arrhythmia or conduction disturbance)
* Patients who are not eligible to have scheduled treatment due to the other significant impaired organ function
* Patients with active bleeding
* Patients who are taking strong CYP3A4 inhibitors, QTc-prolonging drugs, antithrombotic agents, or anti-platelet agents
* Pregnant or nursing women
* Patients who can not swallow the pill
2 Years
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, Republic of Korea
OTHER_GOV
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ki Woong Sung, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-11-147
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.